Minapharm Pharmaceuticals (CAI:MIPH) Inventories, Finished Goods: E£261 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAI:MIPH Minapharm Pharmaceuticals CAI:MIPH
41 GF Score
Price E£760.00
GF Value E£363.21
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Minapharm Pharmaceuticals Inventories, Finished Goods?

Minapharm Pharmaceuticals CAI:MIPH +1.04% 41 Inventories, Finished Goods is E£261 Mil as of Dec. 2025. GuruFocus rates CAI:MIPH with a GF Score™ of 41/100 and a GF Value™ of E£363.21 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Minapharm Pharmaceuticals's quarterly finished goods declined from Jun. 2025 (E£210 Mil) to Sep. 2025 (E£165 Mil) but then increased from Sep. 2025 (E£165 Mil) to Dec. 2025 (E£261 Mil).

Minapharm Pharmaceuticals's annual finished goods increased from Dec. 2023 (E£172 Mil) to Dec. 2024 (E£184 Mil) and increased from Dec. 2024 (E£184 Mil) to Dec. 2025 (E£261 Mil).

Minapharm Pharmaceuticals Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Minapharm Pharmaceuticals's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minapharm Pharmaceuticals Inventories, Finished Goods Chart

Minapharm Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
158.40 130.84 172.01 183.90 260.68

Minapharm Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 183.90 193.78 210.00 164.68 260.68
CAI:MIPH
41GF Score
Minapharm Pharmaceuticals CAI:MIPH
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Minapharm Pharmaceuticals Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of E£261 Mil mean?
Minapharm Pharmaceuticals (CAI:MIPH) has a Inventories, Finished Goods of E£261 Mil as of Dec. 2025. Finished goods are inventory items that are complete and ready to be sold. View historical data on Minapharm Pharmaceuticals and its competitors.
Is Minapharm Pharmaceuticals' Inventories, Finished Goods too high?
Minapharm Pharmaceuticals' current Inventories, Finished Goods is E£261 Mil. Overall, Minapharm Pharmaceuticals has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Minapharm Pharmaceuticals' Inventories, Finished Goods compare to ZTS and UTHR?
Minapharm Pharmaceuticals' Inventories, Finished Goods of E£261 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Drug Manufacturers company?
A good Inventories, Finished Goods depends on the Drug Manufacturers industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Minapharm Pharmaceuticals and its competitors. Minapharm Pharmaceuticals's current Inventories, Finished Goods is E£261 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minapharm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals (CAI:MIPH) is currently considered Significantly Overvalued. The stock's GF Value™ is E£363.21, compared to a current price of E£760.00 — trading 109.2% above its estimated fair value. The current Inventories, Finished Goods is E£261 Mil. Minapharm Pharmaceuticals' overall GF Score™ is 41/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Minapharm Pharmaceuticals (CAI:MIPH), the current Inventories, Finished Goods is E£261 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?

Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued. The current stock price of E£760.00 is trading 109.2% above its estimated GF Value™ of E£363.21. GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for CAI:MIPH:

  • Inventories, Finished Goods: E£261 Mil
  • GF Value™: E£363.21 vs. price of E£760.00 (109.2% above fair value)
  • GF Score™: 41/100 with 10 warning signs

No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Minapharm Pharmaceuticals Business Description

Address El-Bardissi Street, 2T Takseem Asmaa Fahmy Street, Heliopolis, Cairo, EGY
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
41GF Score

Get the complete analysis for CAI:MIPH

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£760.00
Price
E£363.21
GF Value